KDOAM-25
Cat. No.：YN310478
| 产品名称: | KDOAM-25 |
| CAS No.: | 2230731-99-2 |
| Chemical Name: | |
| Synonyms: | KDOAM25;2-[[[2-[2-(Dimethylamino)ethyl-Ethyl-Amino]-2-Oxidanylidene-Ethyl]amino]methyl]pyridine-4-Carboxamide;2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxamide;LQT;KDOAM25A;KDOAM25;KDOAM 25;GTPL8576;BDBM223320;BCP31 |
| 分子量: | 307.39 |
| 分子式: | C15H25N5O2 |
| SMILES: | O=C(C([H])([H])N([H])C([H])([H])C1C([H])=C(C(N([H])[H])=O)C([H])=C([H])N=1)N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | KDOAM-25 是有效，高选择性的组蛋白赖氨酸脱甲基酶 5 (KDM5) 抑制剂，对 KDM5A，KDM5B，KDM5C，KDM5D 的IC50分别为 71 nM，19 nM，69 nM，69 nM。KDOAM-25 可增加转录起始位点的整体 H3K4 甲基化，并损害多发性骨髓瘤 MM1S 细胞的增殖。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
